Germany's BioNTech on Monday lifted its 2025 revenue guidance after receiving initial payments from its new partner Bristol ...

Q3 2025 Earnings Call Transcript November 3, 2025 BioNTech SE misses on earnings expectations. Reported EPS is $-0.14 EPS, ...

Continued clinical execution of oncology strategy with focus on two pan-tumor programs, including combination approaches to address the full ...

BioNTech recently announced it hosted its Innovation Series R&D Day on November 11, 2025, offering an in-depth update on its strategy and clinical pipeline via a public webcast, with replay and ...

BioNTech (NasdaqGS:BNTX) remains unprofitable, with losses worsening at an average rate of 22.1% per year over the last five years. While revenue is forecast to grow at just 1.7% per year, this trails ...

BioNTech reports a Q3 loss but boosts 2025 revenue forecast to €2.6–2.8 billion, driven by Bristol Myers collaboration and cost optimization.

MAINZ, Germany, October 28, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), will host an edition of the Company’s Innovation Series R&D Day at 09:00 a.m. Eastern ...

Backed by fresh European financing, BioNTech’s Kigali facility is emerging as the cornerstone of Africa’s mRNA vaccine ...

Pfizer (PFE) stock is in focus as the company exceeds Street forecasts with its Q3 2025 results thanks mainly to its COVID ...

When BioNTech agreed to acquire rival messenger RNA company CureVac in a $1.25 billion stock deal earlier this summer, some financial analysts said the buyout amounted to an out-of-court settlement of ...

German biotech BioNTech today today reported financial results for the three ended September 30, 2025. The immunotherapy pioneer reported third-quarter revenue of 1.52 billion euros ($1.75 billion, ...

Continued clinical execution of oncology strategy with focus on two pan-tumor programs, including combination approaches to address the full continuum of cancer from early to late disease stagesDemons ...